Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Share:
Related AZN
Pfizer Has Had A Busy M&A Year...Or Has It?
Citi Doesn't See Merck's Lung Cancer Success Lasting Long
Wall Street Breakfast: Pfizer To Buy AstraZeneca Antibiotics Ops (Seeking Alpha)

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Latest Ratings for AZN

DateFirmActionFromTo
Jul 2016Argus ResearchInitiates Coverage onHold
May 2016Leerink SwannMaintainsMarket Perform
Apr 2016Goldman SachsDowngradesNeutralSell

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings

 

Related Articles (AZN)

View Comments and Join the Discussion!